Opendata, web and dolomites

EuroXpand SIGNED

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND

Total Cost €


EC-Contrib. €






 EuroXpand project word cloud

Explore the words cloud of the EuroXpand project. It provides you a very rough idea of what is the project "EuroXpand" about.

discoveries    recovery    expansion    public    75    possession    millions    reference    demonstrated    direct    context    professional    2008    model    eacute    cancer    billion    issue    indirect    post    cardiac    clinical    prevent    35    euros    jobs    death    cells    health    cellprothera    burdensome    pilot    fail    successful    proof    automate    kit    first    founder    worked    prevention    operative    ami    myocardial    2022    safety    stem    global    demonstration    outcomes    thanks    therapy    acute    efficacy    treatments    socio    decreasing    stempack    outstanding    euroxpand    hence    2021    competitors    life    assets    patients    expectancy    innovative    unlike    hf    indicated    surgical    combined    leader    profile    cell    limiting    worldwide    founded    business    industrialised    83    countries    centres    invasive    function    affordable    nor    excellent    treatment    heart    creation    patented    stemxpand    reg    least    total    turnover    thousands    reinsertion    infarction    characterised    pr    position   

Project "EuroXpand" data sheet

The following table provides information about the project.


Organization address
address: 12 RUE DU PARC
postcode: 68100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 5˙000˙000 €
 EC max contribution 5˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2021-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLPROTHERA FR (MULHOUSE) coordinator 5˙000˙000.00


 Project objective

Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development. In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion. The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%. With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 1,9 billion euros in 2021, associated to the creation of at least 40 direct jobs by 2022 and several thousands of indirect jobs, particularly in Cell Therapy Centres.


List of deliverables.
Communication material (brochures, web…) Documents, reports 2020-02-12 17:33:26
Press Release - Project kick-off Documents, reports 2020-02-12 17:33:28

Take a look to the deliverables list in detail:  detailed list of EuroXpand deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EUROXPAND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EUROXPAND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ImmunoSep (2020)

Personalized immunotherapy in sepsis: a precision medicine based approach

Read More